Pfizer hikes full-year outlook on new product growth, taps company veteran as new CFO
CNBC · Annika Kim Constantino ·
Pfizer announced that Cecile Guegan, who has held various leadership roles at the company over the last 20 years, stepped in as CFO this month.
Pfizer on Tuesday reported fiscal third-quarter results that topped estimates and hiked its full-year outlook, as demand for its newly launched and acquired products grows.
Pfizer also Tuesday announced that Cecile Guegan, who has held various finance leadership roles at the company over the last two decades, stepped in as chief financial officer this month. She had served as interim CFO since August, when Pfizer's former CFO, Dave Denton, stepped down to take the same position at Nike.
The company is now expecting full-year revenue to total $62 billion to $64 billion, which compares with a previous outlook of $60.5 billion to $62.5 billion. The low end of that sales range would be roughly flat or down slightly compared with 2025 revenue of $62.6 billion. Still, Pfizer cited its "strong year-to-date performance" as a driver for the guidance hike.